帮助 关于我们

返回检索结果

High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis

查看参考文献26篇

Xue Hongxia 1   Fu Wenyi 1   Cui Huadong 1   Yang Lili 1   Zhang Ning 1 *   Zhao Lijuan 2 *  
文摘 Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern. The current study aimed to observe the incidence of thalidomide-induced peripheral neuropathy among ankylosing spondylitis patients for 1 year after treatment. In this study, 207 ankylosing spondylitis cases received thalidomide treatment, while 116 ankylosing spondylitis cases received other treatments. Results showed that the incidence of thalidomide-induced peripheral neuropathy in the thalidomide group was higher than that in the non-thalidomide group. There was no significant difference in the incidence of neuropathy between the < 6 months medication and ≥ 6 months medication groups. There were no differences in the mean age, gender, or daily dose between the two groups. The incidence of peripheral neuropathy among patients receiving 25, 50, 75, or 100 mg thalidomide per day was 4.6%, 8.5%, 17.1%, 21.7%, respectively. The incidence was significantly different between the groups receiving 25 mg and 100 mg thalidomide. In conclusion, thalidomide can induce peripheral neuropathy within 1 year after treatment of ankylosing spondylitis; however, age and gender have no obvious impact on the incidence of peripheral neuropathy. The incidence of peripheral neuropathy is associated with increasing daily doses of thalidomide.
来源 Neural Regeneration Research ,2015,10(5):814-818 【核心库】
DOI 10.4103/1673-5374.156988
关键词 nerve regeneration ; peripheral nerve injury ; thalidomide ; ankylosing spondylitis ; adverse reactions ; peripheral neuropathy ; prospective study ; treatment ; dose ; treatment time ; age ; sex ; neural regeneration
地址

1. Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Liaoning, Shenyang  

2. Department of Rheumatology and Immunology, the First Affiliated Hospital of China Medical University, Liaoning, Shenyang

语种 英文
文献类型 研究性论文
ISSN 1673-5374
基金 supported by the Natural Science Foundation of Liaoning Province of China
文献收藏号 CSCD:5427560

参考文献 共 26 共2页

1.  Bastuji-Garin S. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol,2002,119:987-1020 被引 2 次    
2.  Brandt J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum,2000,43:1346-1352 被引 13 次    
3.  Briani C. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity,2005,38:549-555 被引 5 次    
4.  Clegg D O. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a department of veterans affairs cooperative study. Arthritis Rheum,1996,39:2004-2012 被引 8 次    
5.  Coelho A. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus, a 65 series of Brazilian patients. Lupus,2005,14:434-439 被引 4 次    
6.  Deng X. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol Int,2013,33:1409-1413 被引 8 次    
7.  Direskeneli H. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin Rheumatol,2008,27:373-375 被引 5 次    
8.  Dougados M. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a sixweek controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum,2001,44:180-185 被引 4 次    
9.  Fernyhough P. Activation of nuclear factor-kappa B via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. J Neurosci,2005,25:1682-1690 被引 6 次    
10.  Frankel H C. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol,2013,52:1407-1409 被引 1 次    
11.  Garcia-Carrasco M. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine,2007,74:500-503 被引 7 次    
12.  Hall V C. Dermatlolgic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol,2003,48:548-552 被引 5 次    
13.  Haslett P A. Thalidomide eostimulates primary human T lymphocytes, preferentially inducing proliferation, eytokine production, and eytotoxie responses in the CD8+ subset. J Exp Med,1998,187:1885-1892 被引 14 次    
14.  Huang F. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum,2002,47:249-254 被引 15 次    
15.  Liu Y. The antiangiogenic effect of thalidomide on occult liver metastases: an in vivo study in mice. J Gastroenterol Hepatol,2009,24:1077-1081 被引 2 次    
16.  Majumdar S. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by eeramide, lipopolyaaceharides, or phorbol ester. J Immunol,2002,168:2644-2651 被引 6 次    
17.  Mark T M. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma,2014,55:2842-2849 被引 1 次    
18.  Morawska M. Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol,2014 被引 7 次    
19.  Matthews S J. Thalidominde: review of approved and investigational uses. Clin Ther,2003,25:342-395 被引 9 次    
20.  Ochonisky S. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol,1994,130:66-69 被引 2 次    
引证文献 2 篇

1 马尧 针刺联合督灸治疗早中期强直性脊柱炎及对骶髂关节骨髓水肿的影响 中国针灸,2022,42(9):971-976
被引 0 次

2 王桂芳 慢性炎性脱髓鞘多发性神经根神经病合并强直性脊柱炎1例报道 中华神经医学杂志,2023,22(2):181-183
被引 0 次

显示所有2篇文献

论文科学数据集
PlumX Metrics
相关文献

 作者相关
 关键词相关
 参考文献相关

版权所有 ©2008 中国科学院文献情报中心 制作维护：中国科学院文献情报中心
地址：北京中关村北四环西路33号 邮政编码：100190 联系电话：(010)82627496 E-mail:cscd@mail.las.ac.cn 京ICP备05002861号-4 | 京公网安备11010802043238号